Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
Designer Receptors Exclusively Activated by Designer Drugs (DREADDs) are chemogenetic tools for remote control of targeted cell populations using chemical actuators that bind to modified receptors. Despite the popularity of DREADDs in neuroscience and sleep research
ResearcherPublications, citations & collaboration network
Designer Receptors Exclusively Activated by Designer Drugs (DREADDs) are chemogenetic tools for remote control of targeted cell populations using chemical actuators that bind to modified receptors. Despite the popularity of DREADDs in neuroscience and sleep research is a researcher indexed in ScholarIQ from OpenAlex & ORCID. ScholarIQ records 1 works, 3 citations, an h-index of 1 and an i10-index of 0.
1
Works
3
Citations
1
h-index
0
i10-index
IDs:OpenAlex
How has Designer Receptors Exclusively Activated by Designer Drugs (DREADDs) are chemogenetic tools for remote control of targeted cell populations using chemical actuators that bind to modified receptors. Despite the popularity of DREADDs in neuroscience and sleep research's publication output changed over time?
ScholarIQpublication output · 2022
1
2022
What are the most-cited papers on Designer Receptors Exclusively Activated by Designer Drugs (DREADDs) are chemogenetic tools for remote control of targeted cell populations using chemical actuators that bind to modified receptors. Despite the popularity of DREADDs in neuroscience and sleep research?
ScholarIQmost cited works
Oral Abstract
Designer Receptors Exclusively Activated by Designer Drugs (DREADDs) are chemogenetic tools for remote control of targeted cell populations using chemical actuators that bind to modified receptors. Despite the popularity of DREADDs in neuroscience and sleep research, potential effects of clozapine-N-oxide (CNO) and other DREADD actuators on sleep have never been systematically tested. Recent reports suggest that CNO can affect brain activity and animal behaviour, putatively through conversion to clozapine. The aim of our study was to assess whether CNO or compound 21 (C21), a novel actuator that cannot convert to clozapine, affect sleep in wild type laboratory mice.
Journal of Sleep Research. 20223 CitationsOPEN ACCESS